Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- The FDA will not meet PDUFA goal dates for Pfizer Inc's (NYSE:PFE) marketing application for abrocitinib for severe atopic dermatitis and the supplemental application for Xeljanz/Xeljanz XR (tofacitinib) for active ankylosing spondylitis.
- The FDA cited its ongoing review of Pfizer's post-marketing safety study, ORAL Surveillance, evaluating tofacitinib in rheumatoid arthritis patients as a factor for the extensions.
- As communicated in April, the FDA had previously extended the PDUFA goal dates to early Q3 2021.
- Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK).
- Xeljanz (tofacitinib) is approved in the U.S. in four indications.
- Price Action: PFE shares are up 0.05% at $41.04 during the premarket session on the last check Thursday.
- Related content: Benzinga's Full FDA Calendar.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!